Kaplan-Meir analysis of overall survival (OS) of the whole cohort and risk factors adversely affecting survival. (A) OS of patients with AL amyloidosis by age group at presentation (75–80 years and >80 years compared with age <75 years). The median OS of the two older age cohorts was 24.2 months and 13.5 months, respectively, compared to 73 months in the younger cohort; (B) OS of patients presenting with ECOG PS 0–1 vs. ECOG 2 vs. ECOG 3–4 - median OS 45.6, 10.4 and 8.7 months, respectively (log rank P<0.0001); (C) OS stratified by presenting dFLC <180 mg/L vs. >180mg/L - median OS 33.9 and 14.3 months, respectively (log rank P=0.001); (D) OS by presenting NYHA class 1–2 vs. NYHA >2 - median OS 37.6 and 8.7 months, respectively (log rank P<0.0001); (E) OS by Mayo stage 1, 2 and 3 - median OS 64, 52.5 and 9.9 months, respectively (log rank P<0.0001); (F) OS by presenting NTproBNP >8500ng/L vs. <8500ng/L - median OS 30 and 8.7 months, respectively (log rank P<0.0001).